drug sequestration
Recently Published Documents


TOTAL DOCUMENTS

33
(FIVE YEARS 3)

H-INDEX

12
(FIVE YEARS 0)

Perfusion ◽  
2021 ◽  
pp. 026765912110281
Author(s):  
Shamir N Kalaria ◽  
Omayma A Kishk ◽  
Mathangi Gopalakrishnan ◽  
Dayanand N Bagdure

Antiepileptic dosing information used to manage neonatal patients receiving extracorporeal membrane oxygenation (ECMO) is limited. The objective of this study is to quantify the extent of sequestration of various antiepileptic drugs using an ex-vivo neonatal ECMO circuit. Two neonatal closed-loop ECMO circuits were prepared using a Rotaflow centrifugal pump, custom polyvinylchloride tubing and a Quadrox-i Neonatal membrane oxygenator. After 5 minutes of circuit priming and stabilization with normal saline/albumin or expired human whole blood, single boluses of levetiracetam (200 mg), lacosamide (20 mg), and phenytoin (200 mg) were injected into the circuit. To account for spontaneous drug degradation, two polyvinylchloride beakers were filled with normal saline/albumin or expired human whole blood and equivalent antiepileptic drug doses were prepared. Simultaneous pharmacokinetic samples were collected from the control solution and the pre-centrifugal pump, pre-oxygenator, and post-oxygenator sampling ports from each circuit. Similar drug recovery profiles were observed among the three sampling sites investigated. Percent drug sequestration after a 24-hour circuit flow period was relatively similar between the two different circuits and ranged between 5.5%–13.2% for levetiracetam, 18.4%–22.3% for lacosamide, and 24.5%–30.2% for phenytoin. A comparison at 12 and 24 hours demonstrated similar percent drug sequestration across all three drugs in each circuit. Percent drug sequestrations for levetiracetam and lacosamide were less than 20% and for phenytoin were as high as 30% based on the sampling following single bolus dose administration into a neonatal ECMO circuit. Careful consideration of patient clinical status should be taken in consideration when optimizing antiepileptic therapy in neonates receiving ECMO.


PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0242342
Author(s):  
Rossana Domenis ◽  
Marco Marino ◽  
Adriana Cifù ◽  
Giulia Scardino ◽  
Francesco Curcio ◽  
...  

Vedolizumab (VDZ) is a therapeutic monoclonal antibody approved for the treatment of inflammatory bowel diseases (IBD). VDZ selectively binds to the α4β7 integrin and blocks trafficking of a specific subset of gastrointestinal-homing T-lymphocytes to inflamed tissue. Although VDZ has shown promising results in numerous clinical studies a subgroup of patients do not respond adequately. Mechanistic insights and prognostic biomarkers able to predict which patients might benefit from VDZ therapy are currently lacking. Circulating exosomes were isolated from serum of blood donors and VDZ-treated patients by polymer-based precipitation. The surface expression of α4β7 integrin was evaluated by flow cytometry and the levels of exosome-bound VDZ were investigated by Promonitor-VDZ ELISA kit. The capacity of exosomes to interfere with the adhesion of VDZ-treated CD4+ T cells was assessed by adhesion assay. In this study, we showed that serum exosomes isolated from both blood donor and ulcerative colitis patients express on their surface the VDZ target α4β7 integrin. We observed an increased exosomal sequestration of VDZ in anti-TNF exposed patients compared to anti- TNFα naïve patients, according to a greater expression of α4β7 integrin on vesicles surface. Circulating exosomes could compete for VDZ binding with CD4+ T cells since we found that the amount of VDZ bound to T cells was impaired in the presence of exosomes. In addition, we demonstrated that exosomes bind VDZ, which consequently becomes unable to block MadCAM-1-mediated adhesion of lymphocytes. Circulating exosomes might contribute to drug sequestration, possibly affecting the therapeutic efficacy of VDZ in IBD patients. Our data suggest that previous biologic therapy may have altered the sequestration capacity of circulating exosomes, thus reducing the efficacy of VDZ in patients who failed anti-TNF agents.


2020 ◽  
Vol 21 (12) ◽  
pp. 4392 ◽  
Author(s):  
Jan Hraběta ◽  
Marie Belhajová ◽  
Hana Šubrtová ◽  
Miguel Angel Merlos Rodrigo ◽  
Zbyněk Heger ◽  
...  

Resistance to chemotherapeutics and targeted drugs is one of the main problems in successful cancer therapy. Various mechanisms have been identified to contribute to drug resistance. One of those mechanisms is lysosome-mediated drug resistance. Lysosomes have been shown to trap certain hydrophobic weak base chemotherapeutics, as well as some tyrosine kinase inhibitors, thereby being sequestered away from their intracellular target site. Lysosomal sequestration is in most cases followed by the release of their content from the cell by exocytosis. Lysosomal accumulation of anticancer drugs is caused mainly by ion-trapping, but active transport of certain drugs into lysosomes was also described. Lysosomal low pH, which is necessary for ion-trapping is achieved by the activity of the V-ATPase. This sequestration can be successfully inhibited by lysosomotropic agents and V-ATPase inhibitors in experimental conditions. Clinical trials have been performed only with lysosomotropic drug chloroquine and their results were less successful. The aim of this review is to give an overview of lysosomal sequestration and expression of acidifying enzymes as yet not well known mechanism of cancer cell chemoresistance and about possibilities how to overcome this form of resistance.


2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Ben Zhao ◽  
Laura Dierichs ◽  
Jiang-Ning Gu ◽  
Marija Trajkovic-Arsic ◽  
Ralf Axel Hilger ◽  
...  

2019 ◽  
Vol 21 (1) ◽  
pp. 28-32 ◽  
Author(s):  
CIS Meadows ◽  
M Toolan ◽  
A Slack ◽  
S Newman ◽  
M Ostermann ◽  
...  

The diagnosis of death using neurological criteria is an important legal method of establishing death in the UK. The safety of the diagnosis lies in the exclusion of conditions which may mask the diagnosis and the testing of the fundamental reflexes of the brainstem including the apnoea reflex. Extracorporeal membrane oxygenation for cardiac or respiratory support can impact upon these tests, both through drug sequestration in the circuit and also through the ability to undertake the apnoea test. Until recently, there has been no nationally accepted guidance regarding the conduct of the tests to undertake the diagnosis of death using neurological criteria for a patient on extracorporeal membrane oxygenation. This article considers both the background to and the process of guideline development.


ASAIO Journal ◽  
2019 ◽  
Vol 65 (2) ◽  
pp. 187-191 ◽  
Author(s):  
Viviane G. Nasr ◽  
Jonathan Meserve ◽  
Luis M. Pereira ◽  
David Faraoni ◽  
Steve Brediger ◽  
...  

2019 ◽  
Vol 21 (13) ◽  
pp. 7127-7136
Author(s):  
Aruna K. Mora ◽  
Arghyadeep Basu ◽  
Rahul Kalel ◽  
Sukhendu Nath

We have demonstrated that the drug sequestration power of cationic surfactant is enhanced and its protein denaturing capability is suppressed significantly through its incorporation in bio-compatible Pluronic micelles.


Sign in / Sign up

Export Citation Format

Share Document